Covaxin shows 77.8% efficacy in phase 3 trial data: All you need to know

Hyderabad News: Hyderabad based Bharat Biotech on Saturday announced a final analysis for its vaccine Covaxin effectiveness from phase-3 clinical trial claiming it to be 77.8 percent successful against COVID-19.

Effectiveness investigation exhibits that the Covaxin to be 77.8 percent viable against symptomatic COVID-19, through evaluation of 130 affirmed cases, with 24 saw in the antibody group versus 106 in the fake treatment group.

Effectiveness investigation exhibits that Covaxin to be 93.4 percent working and curing against serious suggestive COVID-19, the organization said.

Bharat Biotech Phase 3 Results | Covaxin releases their interim analysis from phase three trials

Adding to the statement it also said that Covaxin gives 65.2 percent protection against the SARS-CoV-2, B.1.617.2 Delta variants. 

Also Read Gap for Covishield second dose increased for 14-16 weeks

As per the Bharat Biotech, safety analysis demonstrates adverse events reported were similar to inactive drugs, with around 12 percent of the volunteers experiencing commonly known side effects and less than 0.5 percent of volunteers feeling serious adverse effects.

Hyderabad based vaccine production claimed that their vaccin Covaxin was well authorized and the Data Safety Monitoring Board has not reported any safety concerns related to the vaccine.

The overall amount of adverse events seen in the Covaxin was lower than that observed in other COVID-19 vaccines. 

Bharat Biotech has not sought security for Covaxin from the governments as of now.

Effectiveness data exhibits 63.6 percent protection for the asymptomatic COVID-19.

Efficacy data exhibits 65.2 percent protection against the SARS-CoV-2, B.1.617.2 new Delta variant, Bharat Biotech said.

“Covaxin Phase 3 Trial Results Released” – Bharat Biotech

The successful protection and effectiveness seen in the Covaxin as a result of conducting the largest ever COVID vaccines trials in the country establishes the ability of India and the developing countries of the world to focus on innovation and novel product innovation.

We are very much proud to say that innovation from India will now be available to protect the people globally, said Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech.

A clinical trial to determine the protection and immunogenicity of a booster dose is also in progress.

Many more research activities are also being carried out to study the new variants of concern and to examine their suitability for follow up booster doses in future the company said.

Bharat Biotech also said that its promise to continue development of Covaxin is also underway with additional clinical trials to ensure safety and effectiveness in children between 2-18 years of age group.

It alleged that Covaxin has been evaluated through neutralising antibody responses against many new variants of concerns as well, namely B.1.617.2 (Delta), B.1.617.1 (Kappa), B.1.1.7 (Alpha), B.1.351 (Beta), P2- B.1.1.28 (Gamma).

Register now on cowin registration website

It’s effectiveness is much more successful in new variants compared to other vaccines.

One thought on “Covaxin shows 77.8% efficacy in phase 3 trial data: All you need to know

Leave a Reply

Your email address will not be published. Required fields are marked *